SEC Form SC 13G filed by Selecta Biosciences Inc.

2/9/24 8:50:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SELB alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 CARTESIAN THERAPEUTICS INC COMMON STOCK Cusip #816212104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #816212104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 13,242,175 Item 6: 0 Item 7: 13,256,374 Item 8: 0 Item 9: 13,256,374 Item 11: 8.186% Item 12: HC Cusip #816212104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 13,256,374 Item 8: 0 Item 9: 13,256,374 Item 11: 8.186% Item 12: IN Item 1(a). Name of Issuer: CARTESIAN THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 65 GROVE STREET WATERTOWN, MA 02472 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 816212104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 13,256,374 (b) Percent of Class: 8.186% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 13,256,374 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CARTESIAN THERAPEUTICS INC. The interest of Select Biotechnology Portfolio, in the COMMON STOCK of CARTESIAN THERAPEUTICS INC, amounted to 12,973,413 shares or 8.011% of the total outstanding COMMON STOCK at December 29, 2023. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CARTESIAN THERAPEUTICS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $SELB alert in real time by email

Date	Price Target	Rating	Analyst
8/18/2023	$1.00	Outperform → Market Perform	SVB Securities
6/14/2022	$6.00 → $5.00	Buy	Needham
6/6/2022	$7.00	Outperform	SVB Leerink
11/1/2021	$6.00 → $7.00	Buy	Needham

SEC Form SC 13G filed by Selecta Biosciences Inc.

Chat with this insight

Recent Analyst Ratings for
$SELB

$SELB
SEC Filings

SEC Form DEFA14A filed by Selecta Biosciences Inc.

SEC Form DEF 14A filed by Selecta Biosciences Inc.

SEC Form PRE 14A filed by Selecta Biosciences Inc.

$SELB
Financials

Live finance-specific insights

Selecta Biosciences Announces Merger with Cartesian Therapeutics

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

$SELB
Leadership Updates

Live Leadership Updates

Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

Surface Oncology Appoints Carsten Brunn to Board of Directors

Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer

$SELB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SELB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Selecta Biosciences downgraded by SVB Securities with a new price target

Needham reiterated coverage on Selecta Biosciences with a new price target

SVB Leerink initiated coverage on Selecta Biosciences with a new price target

SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)